Creating an index to measure health state of depressed patients in automated healthcare databases: the methodology

Autor: Adrian Tanasescu, Ylana Chalem, Francois-Xavier Lamy, N Despiégel, Patrice Verpillat, D. Saragoussi, Clément François, Alan G Wade, Pierre-Michel Llorca, Christophe Lançon, Bruno Falissard, Djamel A. Zighed

Publikováno v: Journal of Market Access & Health Policy
Journal of Market Access & Health Policy, Taylord & Francis, 2017, 5 (1), ⟨10.1080/20016689.2017.1372025⟩
Journal of Market Access & Health Policy, Vol 5, Iss 1 (2017)
Journal of Market Access & Health Policy, 2017, 5 (1), ⟨10.1080/20016689.2017.1372025⟩

Background and objective: Automated healthcare databases (AHDB) are an important data source for real life drug and healthcare use. In the filed of depression, lack of detailed clinical data requires the use of binary proxies with important limitatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90a9c4a68acf36ea887c4002b2edfd7b
https://hal.uca.fr/hal-01696793

PCN113 COST-MINIMISATION AND FIVE-YEAR BUDGET IMPACT ANALYSIS FOR MVASI® (BEVACIZUMAB BIOSIMILAR) IN ITALY

Autor: N. Despiégel, L. Cirillo, I. Gaikwad

Publikováno v: Value in Health. 22:S458

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::de6e044749a5da636184d775cfbf8307
https://doi.org/10.1016/j.jval.2019.09.310

The Use and Performance of Productivity Scales to Evaluate Presenteeism in Mood Disorders

Autor: N Despiégel, Clément François, Benedikte R Lensberg, Natalya Danchenko, Michael Drummond

Publikováno v: Value in Health. 15(8):1148-1161

Objective Mood disorders are associated with a high societal cost, mainly due to presenteeism. The objective of this study was to review the use of 10 instruments that rate presenteeism in mood disorders and to provide recommendations regarding the a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11fa3e89652f2f56a90be7ba65e4479d

Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK

Autor: Clément François, D. Saragoussi, N Despiégel, Florent Guelfucci, Alan G Wade, Mondher Toumi

Publikováno v: Current Medical Research and Opinion. 26:1161-1170

To retrospectively compare the 12-month healthcare utilisation and direct medical costs associated with the use of escitalopram, generic SSRIs, and venlafaxine in patients with severe depression in the United Kingdom (UK).Data for this retrospective

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc3000e6b6d4a49dc4511a45cda826b0
https://doi.org/10.1185/03007991003738519

Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder

Autor: S. Aballéa, Clément François, S. A. Montgomery, P. Auquier, N Despiégel, J. Roïz

Publikováno v: International Journal of Clinical Practice. 62:1693-1702

Background: Social anxiety disorder (SAD) is associated with substantial reduction in health-related quality of life (HRQoL). Escitalopram has proven efficacy in the short-term treatment of SAD and prevention of relapse.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c6de53fb9e1198ab70537f526790b5c2
https://doi.org/10.1111/j.1742-1241.2008.01879.x